Cullinan Oncology, Inc. announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.13 USD | -1.66% | -7.99% | +156.43% |
May. 09 | Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing | MT |
Apr. 29 | Cullinan Therapeutics Appoints Mary Kay Fenton as CFO | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+156.43% | 1.13B | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+44.19% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines